Metagenomi Therapeutics (MGX) Interest & Investment Income (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Interest & Investment Income for 4 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 46.69% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $8.1 million (down 40.61% YoY), while the FY2025 annual figure was $9.5 million, down 35.67% from the prior year.
• Interest & Investment Income eased to $1.5 million in Q1 2026 per MGX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.0 million in Q1 2023 and bottomed at $1.5 million in Q1 2026.
• Historically, Interest & Investment Income has averaged $3.2 million across 4 years, with a median of $3.6 million in 2024.
• Annual changes were most pronounced in 2024 — Interest & Investment Income grew 0.23% — and 2026, when it tumbled 46.69%.
• Metagenomi Therapeutics' Interest & Investment Income stood at $3.6 million in 2023, then dropped by 12.0% to $3.2 million in 2024, then sank by 41.05% to $1.9 million in 2025, then dropped by 18.31% to $1.5 million in 2026.
• Business Quant data shows MGX's Interest & Investment Income at $1.5 million in Q1 2026, $1.9 million in Q4 2025, and $2.2 million in Q3 2025.